Shannon Thyme Klinger - 06 Jun 2025 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Legal Officer
Signature
/s/ James Dillon, as Attorny-in-Fact
Issuer symbol
MRNA
Transactions as of
06 Jun 2025
Transactions value $
-$14,392
Form type
4
Date filed
09 Jun 2025, 16:20
Previous filing
02 Jun 2025
Next filing
29 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Klinger Shannon Thyme Chief Legal Officer C/O MODERNA, INC., 325 BINNEY STREET, CAMBRIDGE /s/ James Dillon, as Attorny-in-Fact 2025-06-09 0001866132

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise +1.14K +4.23% 28K 06 Jun 2025 Direct F1, F2
transaction MRNA Common Stock Tax liability -$14.4K -551 -1.97% $26.12 27.5K 06 Jun 2025 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Restricted Stock Units Options Exercise $0 -1.14K -100% $0.00 0 06 Jun 2025 Common Stock 1.14K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 Includes 595 shares acquired under the Moderna, Inc. 2018 Employee Stock Purchase Plan on May 30, 2025.
F3 Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.
F4 25% of the shares subject to this restricted stock unit award vested on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter. This restricted stock unit award is fully vested as of June 6, 2025.